Value through Innovation27 July 2016

Clinical Study Results

  • MICARDIS ® - Cardiovascular Diseases
    Clinical Study Number 502.373
    Study Indication Cardiovascular Diseases
    Product MICARDIS ®
    Generic Name Telmisartan
    Lab Code
    Clinical Phase III
    Study Title

    1.ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). A large, simple, randomised, double-blind, multicentre, international trial comparing the effects of telmisartan, ramipril and their combination on outcomes in patients at high risk for cardiovascular events. 2. Telmisartan Randomized AssessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND). A large, simple, randomized, double-blind, multicentre, international trial comparing the effects of telmisartan with placebo on outcomes in patients at high risk for cardiovascular events and intolerant of ACE-I

    Study Document Trial synopsis 502.373 Ontarget_CO english Trial synopsis 502.373 Transcend_CO english
  • PRADAXA ® - Cardiovascular Diseases
    Clinical Study Number 1160.121
    Study Indication Cardiovascular Diseases
    Product PRADAXA ®
    Generic Name Dabigatran
    Lab Code
    Clinical Phase I
    Study Title

    Open label, non randomized, multiple dose Phase I study to investigate the elimination, pharmacokinetics, pharmacodynamics and safety of dabigatran etexilate (Pradaxa®) under steady state conditions before, during and after haemodialysis in patients with End Stage Renal Disease (ESRD) undergoing regular haemodialysis

    Study Document Trial synopsis 1160.121 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.